Elevated concentrations of NF-L have been consistently identified in the CSF of individuals diagnosed with MS, indicating that NF-L may serve as a significant biomarker for assessing disease activity, as well as the efficacy of various therapeutic interventions for MS [31]. The gene discussed is NEFL; the disease is myeloid sarcoma.